View in EDS

Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

Saved in:
Bibliographic Details
Title: Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C
Authors: Nielsen, Mette J., Veidal, Sanne S., Karsdal, Morten A., Ørsnes-Leeming, Diana J., Vainer, Ben, Gardner, Stephen D., Hamatake, Robert, Goodman, Zachary D., Schuppan, Detlef, Patel, Keyur
Source: Nielsen, M J, Veidal, S S, Karsdal, M A, Orsnes-Leeming, D J, Vainer, B, Gardner, S D, Hamatake, R, Goodman, Z D, Schuppan, D & Patel, K 2015, ' Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C ', Liver International, vol. 35, no. 2, pp. 429-437 . https://doi.org/10.1111/liv.12700
Publisher Information: Wiley, 2014.
Publication Year: 2014
Subject Terms: Liver Cirrhosis, 0301 basic medicine, Collagen Type III/blood, 0303 health sciences, Liver fibrosis, Enzyme-Linked Immunosorbent Assay, Biomarker, Hepatitis C, Chronic, Prognosis, Hepatitis C, 3. Good health, Cohort Studies, 03 medical and health sciences, Collagen Type III, Chronic/blood, Predictive Value of Tests, Multivariate Analysis, Extracellular matrix remodelling, Disease Progression, Humans, Chronic, Hepatitis C, Chronic/blood, Liver Cirrhosis/diagnosis, Biomarkers/blood, Biomarkers
Description: Background & AimsFibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N‐terminal propeptide of type III collagen (Pro‐C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients.MethodPro‐C3 and C3M were measured by ELISA in plasma from CHC patients (n = 194) from a prior phase II antifibrotic trial (NCT00244751). Plasma samples and paired liver biopsies were obtained at baseline and after 1‐year. Patients were stratified according to Ishak stages 2‐4. Internal cross‐validation was performed by bootstrap analysis.ResultsPro‐C3 levels were significantly higher in CHC patients in Ishak stage 4 compared to stage 2 (P P AUC = 0.72, P P = 0.007) levels was observed between the groups of −1, 0, +1 and +2 change in Ishak stage at 12 months. Pro‐C3 was significantly increased in group +1 (P = 0.030) and +2 (P = 0.021) compared to group 0. No significant differences were observed for C3M. In multivariate analysis, only baseline Pro‐C3, but not FibroTest, had an independent association with fibrosis progression.ConclusionsPro‐C3 is a useful test to predict fibrogenesis and monitor disease progression. Moreover, it could differentiate mild from moderate disease. Pro‐C3 may become a promising blood parameter be included in future studies for monitoring disease progression and eventually for evaluation of potential antifibrotic therapies.
Document Type: Article
Language: English
ISSN: 1478-3231
1478-3223
DOI: 10.1111/liv.12700
Access URL: https://pubmed.ncbi.nlm.nih.gov/25308921
https://www.ncbi.nlm.nih.gov/pubmed/25308921
https://pubmed.ncbi.nlm.nih.gov/25308921/
https://onlinelibrary.wiley.com/doi/10.1111/liv.12700
https://portal.findresearcher.sdu.dk/da/publications/f1171e1b-5fe6-458b-85c0-1c46bd920387
https://portal.findresearcher.sdu.dk/da/publications/f1171e1b-5fe6-458b-85c0-1c46bd920387
https://doi.org/10.1111/liv.12700
Rights: Wiley Online Library User Agreement
Accession Number: edsair.doi.dedup.....df916a8128fac21999e7f691ddec3a0f
Database: OpenAIRE
Description
Abstract:Background & AimsFibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N‐terminal propeptide of type III collagen (Pro‐C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients.MethodPro‐C3 and C3M were measured by ELISA in plasma from CHC patients (n = 194) from a prior phase II antifibrotic trial (NCT00244751). Plasma samples and paired liver biopsies were obtained at baseline and after 1‐year. Patients were stratified according to Ishak stages 2‐4. Internal cross‐validation was performed by bootstrap analysis.ResultsPro‐C3 levels were significantly higher in CHC patients in Ishak stage 4 compared to stage 2 (P P AUC = 0.72, P P = 0.007) levels was observed between the groups of −1, 0, +1 and +2 change in Ishak stage at 12 months. Pro‐C3 was significantly increased in group +1 (P = 0.030) and +2 (P = 0.021) compared to group 0. No significant differences were observed for C3M. In multivariate analysis, only baseline Pro‐C3, but not FibroTest, had an independent association with fibrosis progression.ConclusionsPro‐C3 is a useful test to predict fibrogenesis and monitor disease progression. Moreover, it could differentiate mild from moderate disease. Pro‐C3 may become a promising blood parameter be included in future studies for monitoring disease progression and eventually for evaluation of potential antifibrotic therapies.
ISSN:14783231
14783223
DOI:10.1111/liv.12700